I have so much empathy for the employers and patients who are navigating the GLP-1 landscape right now. BCBS Michigan announced last month that they are dropping coverage for their fully insured population after “careful consideration of GLP-1 weight loss drugs' efficacy, safety and access, and cost.” It’s heartbreaking that there is so much uncertainty on how to effectively cover GLP-1s. This topic dominated talks I heard at AHIP last month. Whether a group decides not to cover at all or limit access through PA, time limits, or narrow prescribing networks - sponsors are working hard to figure this out. But the one thing that remains clear is that regardless of what path is chosen, comprehensive lifestyle change must remain front and center. At Omada Health, we’ve seen that higher engagement with our programs alongside GLP-1 use leads to more weight loss than GLP-1s alone. Equipping people with the support they need to succeed long-term on these drugs has to be a bigger part of the conversation. https://buff.ly/3LMB8ZL
Carolyn Bradner Jasik, MD’s Post
More Relevant Posts
-
A tiered approach to the allocation of GLP-1 medications to ensure the highest risk groups and those most likely to benefit from weight loss have full access. This approach utilizes a health equity lens as well as a cost effectiveness model that I believe is very useful as we think through how to best distribute these drugs. #Healthequity #Obesity #GLP1 #NEJM
-
-
New research suggests that nearly 60% of patients on GLP-1s stop treatment within 3 months–well before they’re able to see all of the potential benefits. Medication adherence, cost, and unclear ROI are among the many reasons employers are cautious about providing coverage for this class of drugs, but weight care doesn't have to rely on them. Alternative anti-obesity medications (AOMs) are paving a path for employers actively working to improve employees' health while enabling them to control costs. We sat down with Dr. Rekha Kumar, M.D, M.S., Chief Medical Officer, for a Q&A to gain insights into GLP-1 prescribing, AOMs, cost-containment strategies, and more. Check out the article 💡https://lnkd.in/e5FdVQUm #healthcare #weightcare #obesity #employeewellbeing
-
-
Host of Techstination and Co-host of the Smart Driving Cars and Living Longer Better Smarter podcasts
https://lnkd.in/emSf2PVB What can we learn about healthy aging from other countries and cultures? And what you should know about new caps on Medicare Part D prescription drug costs. Mary and Fred are joined by AARP Director of Global Aging Vijeth Iyengar and then by Leigh Purvis, Prescription Drug Policy Principal at AARP Public Policy. Tune in to episode 78 of What's Next Living Longer Better Smarter: Lessons for Healthy Aging.
-
-
Worth your time to learn about the businesses that come between you, your pharmacist and the manufacturers that actually produce your medicines. There are real problems with middlemen in the supply chain that need addressing.
The New York Times pulled back the curtain on the shady practices of PBMs. These middlemen decide what medicines patients can get and at what cost. They pocket savings meant for patients and are “driving up drug costs for millions of people, employers and the government.” Policymakers must act now. More: https://lnkd.in/ecGHeBKD
-
-
With the rise of high-cost medications like GLP-1s, designing benefits that offers optimal health outcomes and equitable access can be a challenge. Join us on June 25th to learn more about apree's new medication and weight loss management program helping members with long-term impact and financial sustainability. #glp1s #pharmacyspend #employeebenefits https://lnkd.in/gfVi_RYu
-
It seems not a day goes by without a new headline about GLP-1s—the weight care space is constantly evolving and many uncertainties remain. On November 13, Rock Health Advisory will host a webinar designed to answer the burning questions of enterprise innovation leaders interested in building, buying, or implementing solutions in the weight care space. Through conversations with our panelists Elina Onitskansky (Ilant Health), Kevin Kumler (Virta Health), Brooke Boyarsky Pratt (knownwell), and Cara Bohon (Equip), we will shed light on emerging trends in weight care and explore: • What happens with compounded GLP-1 options (and the companies that are offering them) as GLP-1 shortages are resolved? • Are weight care drugs a “lifetime drug” or not? Is it realistic to expect to wean people off—and if so, what support will they need? • What impact might weight care drugs have on mental health and health outcomes more broadly? 📅 November 13, 2024 ⏰ 9 AM PT/12 PM ET ➡️ Register here: https://lnkd.in/gFXveru5 #WeightCare #DigitalHealth #HealthcareInnovation
-
-
You Can Know More. Have More. Live More | Investment News Women to Watch Awardee - Financial Literacy Champion, 2024 | Educator | Speaker | Podcast Host | Author | Mom | Founder, Her Retirement & Retirement Solved
Great article here.
Nearly three in 10 Americans struggle to afford the medications they need. In my new story for TIME, patients and experts share strategies that can result in dramatic savings on prescription drugs—creative workarounds that might be able to save you hundreds, or even thousands, on your meds too. Huge thanks to the many people who shared their stories and tips with me and the compassionate experts who shared their insights and advice, especially the amazing folks at Patients For Affordable Drugs (h/t Merith Basey, Emma Sands, Ian Seepersaud), health policy professor Stacie Dusetzina at the Vanderbilt University Medical Center and Richard Sagall, founder of NeedyMeds. https://lnkd.in/etDGiqsz
-
Helping commercial and public sector employers, unions, health plans and health systems halve pharmacy costs through education and radical transparency with TransparentRx.
🌟 The landscape of employer-sponsored pharmacy benefits is evolving rapidly, and the latest surge in coverage for GLP-1 drugs is a testament to that. GLP-1 medications, known for their effectiveness in managing diabetes and aiding weight loss, are becoming a focal point in employer benefits plans. This shift not only addresses critical health issues but also reflects a broader commitment to employee well-being. 📈 #EmployeeWellbeing #HealthcareInnovation #BenefitsManagement #PharmacyBenefits #GLP1Drugs #EmployerSponsoredHealthCare
Employer Coverage of GLP-1 Drugs Jumps [Weekly Roundup]
https://transparentrx.com
-
🌟 The landscape of employer-sponsored pharmacy benefits is evolving rapidly, and the latest surge in coverage for GLP-1 drugs is a testament to that. GLP-1 medications, known for their effectiveness in managing diabetes and aiding weight loss, are becoming a focal point in employer benefits plans. This shift not only addresses critical health issues but also reflects a broader commitment to employee well-being. 📈 #EmployeeWellbeing #HealthcareInnovation #BenefitsManagement #PharmacyBenefits #GLP1Drugs #EmployerSponsoredHealthCare
Employer Coverage of GLP-1 Drugs Jumps [Weekly Roundup]
https://transparentrx.com
-
🌟 The landscape of employer-sponsored pharmacy benefits is evolving rapidly, and the latest surge in coverage for GLP-1 drugs is a testament to that. GLP-1 medications, known for their effectiveness in managing diabetes and aiding weight loss, are becoming a focal point in employer benefits plans. This shift not only addresses critical health issues but also reflects a broader commitment to employee well-being. 📈 #EmployeeWellbeing #HealthcareInnovation #BenefitsManagement #PharmacyBenefits #GLP1Drugs #EmployerSponsoredHealthCare
Employer Coverage of GLP-1 Drugs Jumps [Weekly Roundup]
https://transparentrx.com
I simplify your professional expertise into clear, engaging content that builds your authority and attracts your audience. I'm on a mission to save LinkedIn from boring content.
4moComprehensive lifestyle change will always be more cost-effective, and it has no side effects either.